O	0	1	[
O	1	9	Clinical
O	10	15	value
O	16	18	of
O	19	27	combined
O	28	35	therapy
O	36	40	with
B-intervention	41	46	188Re
I-intervention	46	47	-
I-intervention	47	51	HEDP
I-intervention	52	55	and
I-intervention	56	67	pamidronate
O	68	70	in
O	71	77	breast
O	78	84	cancer
O	85	89	with
O	90	94	bone
O	95	105	metastasis
O	105	106	]
O	106	107	.

O	108	110	To
O	111	119	evaluate
O	120	123	the
O	124	132	clinical
O	133	144	therapeutic
O	145	150	value
O	151	153	of
O	154	155	(
O	155	158	188
O	158	159	)
O	159	161	Re
O	161	162	-
O	162	166	HEDP
O	167	175	combined
O	176	180	with
O	181	192	pamidronate
O	193	195	in
O	196	202	breast
O	203	209	cancer
O	210	214	with
O	215	219	bone
O	220	230	metastasis
O	230	231	.

B-total-participants	232	237	Forty
I-total-participants	237	238	-
I-total-participants	238	243	eight
B-eligibility	244	252	patients
I-eligibility	253	257	with
I-eligibility	258	264	breast
I-eligibility	265	271	cancer
I-eligibility	272	276	with
I-eligibility	277	282	multi
I-eligibility	282	283	-
I-eligibility	283	287	bone
I-eligibility	288	298	metastases
O	299	303	were
O	304	312	randomly
O	313	320	divided
O	321	325	into
O	326	331	three
O	332	338	groups
O	338	339	:
B-control-participants	339	341	15
O	342	350	patients
O	351	359	received
B-control	360	361	(
I-control	361	364	188
I-control	364	365	)
I-control	365	367	Re
I-control	367	368	-
I-control	368	372	HEDP
O	373	374	(
O	374	379	group
O	380	381	A
O	381	382	)
O	382	383	,
B-control-participants	384	386	15
O	387	395	patients
O	396	404	received
B-control	405	416	pamidronate
O	417	418	(
O	418	423	group
O	424	425	B
O	425	426	)
O	427	430	and
B-intervention-participants	431	433	18
O	434	442	patients
O	443	447	were
O	448	455	treated
O	456	458	by
O	459	460	(
O	460	463	188
O	463	464	)
O	464	466	Re
O	466	467	-
O	467	471	HEDP
O	472	476	plus
O	477	488	pamidronate
O	489	490	(
O	490	495	group
O	496	497	C
O	497	498	)
O	498	499	.

O	500	503	The
B-outcome	504	511	overall
I-outcome	512	516	pain
I-outcome	517	523	relief
I-outcome	524	528	rate
O	529	532	was
B-cv-bin-percent	533	535	73
I-cv-bin-percent	535	536	.
I-cv-bin-percent	536	537	3
I-cv-bin-percent	537	538	%
O	538	539	,
B-cv-bin-percent	540	542	80
I-cv-bin-percent	542	543	.
I-cv-bin-percent	543	544	0
I-cv-bin-percent	544	545	%
O	545	546	,
B-iv-bin-percent	547	550	100
I-iv-bin-percent	550	551	.
I-iv-bin-percent	551	552	0
I-iv-bin-percent	552	553	%
O	554	556	in
O	557	563	groups
O	564	565	A
O	565	566	,
O	567	568	B
O	569	572	and
O	573	574	C
O	574	575	.

O	576	579	The
B-outcome	580	588	response
I-outcome	589	593	rate
I-outcome	594	596	of
I-outcome	597	601	bone
I-outcome	602	612	metastasis
O	613	616	was
B-cv-bin-percent	617	619	40
I-cv-bin-percent	619	620	.
I-cv-bin-percent	620	621	0
I-cv-bin-percent	621	622	%
O	622	623	,
B-cv-bin-percent	624	626	33
I-cv-bin-percent	626	627	.
I-cv-bin-percent	627	628	3
I-cv-bin-percent	628	629	%
O	629	630	,
B-iv-bin-percent	631	633	66
I-iv-bin-percent	633	634	.
I-iv-bin-percent	634	635	7
I-iv-bin-percent	635	636	%
O	637	639	in
O	640	646	groups
O	647	648	A
O	648	649	,
O	650	651	B
O	652	655	and
O	656	657	C
O	658	670	respectively
O	670	671	.

O	672	675	The
B-outcome	676	687	therapeutic
I-outcome	688	694	effect
O	695	697	of
O	698	703	group
O	704	705	C
O	706	709	was
O	710	716	better
O	717	721	than
O	722	727	those
O	728	730	of
O	731	737	groups
O	738	739	A
O	740	743	and
O	744	745	B
O	746	747	(
O	747	748	P
O	749	750	<
O	751	752	0
O	752	753	.
O	753	755	05
O	755	756	)
O	756	757	,
O	758	765	without
O	766	769	any
O	770	782	significance
O	783	785	in
O	786	789	the
O	790	800	difference
O	801	802	(
O	802	803	P
O	804	805	>
O	806	807	0
O	807	808	.
O	808	810	05
O	810	811	)
O	811	812	.

O	813	816	The
O	817	828	therapeutic
O	829	835	effect
O	836	838	of
O	839	840	(
O	840	843	188
O	843	844	)
O	844	846	Re
O	846	847	-
O	847	851	HEDP
O	852	860	combined
O	861	865	with
O	866	877	pamidronate
O	878	881	for
O	882	888	breast
O	889	895	cancer
O	896	900	with
O	901	905	bone
O	906	916	metastasis
O	917	919	is
O	920	930	remarkable
O	931	933	in
O	934	938	bone
O	939	943	pain
O	944	950	relief
O	951	954	and
O	955	959	bone
O	960	970	metastasis
O	971	978	control
O	978	979	,
O	980	985	which
O	986	988	is
O	989	995	better
O	996	1000	than
O	1001	1007	either
O	1008	1009	(
O	1009	1012	188
O	1012	1013	)
O	1013	1015	Re
O	1015	1016	-
O	1016	1020	HEDP
O	1021	1023	or
O	1024	1035	pamidronate
O	1036	1041	alone
O	1041	1042	.
